The FDA’s approval of teplizumab for newly diagnosed pediatric Type 1 diabetes marks a shift from insulin replacement toward preserving remaining beta-cell function through immunotherapy.
Comments
0
Be the first to comment
Sign up now and become a member of the TheBrief.Health community!
Comments
0Be the first to comment
Sign up now and become a member of the TheBrief.Health community!